A randomized, double-blind phase 2 study assessed the efficacy and safety of sacubitril/allisartan, an angiotensin receptor neprilysin inhibitor, compared with placebo in Chinese patients with mild to moderate hypertension
Latest Information Update: 25 Aug 2023
At a glance
- Drugs Alisartan/sacubitril-Shenzhen Salubris Pharmaceuticals (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Therapeutic Use
Most Recent Events
- 25 Aug 2023 New trial record